CRISPR Therapeutics AG

CRSPNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

96.7M

on 2026-06-30, from 84.8M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

S-3ASR of 2024-08-05. Not read yet. S-3ASR ↗

$600.0M

Jefferies, agreement of 2025-10-15. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-03 is not read yet.

Cash

25.6 quarters

$2.36B on 2026-06-30 ÷ $92.4M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-05-19	Public offering	1,842,105	not read	not read	424B5 ↗

Also on file: $50.0M convertible notes, 2026-03-16 8-K ↗